Condensed Consolidated Statements Of Cash Flows (Unaudited) (USD $) In Thousands, unless otherwise specified	3 Months Ended
	Mar. 31, 2013	Mar. 31, 2012
Cash Flows from Operating Activities
Net income	$ 1,477	$ 1,876
Adjustments to reconcile net income to net cash provided by (used in) operating activities:
Depreciation and amortization	2,968	2,935
Gain on sale of bioplastics manufacturing business	(1,453)
Gain on sale of joint venture interest		(4,055)
Loss on sale of assets		48
Share based compensation	353	353
Equity in (earnings) loss	942	(437)
Changes in operating assets and liabilities:
Restricted cash	12	1,454
Receivables, net	980	(7,984)
Inventory	(2,539)	(3,236)
Prepaid expenses	(654)	(409)
Refundable income taxes	(38)	120
Accounts payable	3,603	(1,880)
Accounts payable to affiliate, net	(3,287)	(1,380)
Accrued expenses	529	904
Change in derivatives		1,131
Deferred credit	(97)	(150)
Accrued retirement health and life insurance benefits and other noncurrent liabilities	(242)	(261)
Net cash provided by (used in) operating activities	2,554	(10,971)
Cash Flows from Investing Activities
Proceeds from sale of bioplastics manufacturing business	2,797
Proceeds from sale of joint venture interest		9,103
Proceeds from the disposition of property and equipment		2,232
Additions to property and equipment	(798)	(484)
Investment in and advances to unconsolidated subsidiaries		(500)
Net cash provided by investing activities	1,999	10,351
Cash Flows from Financing Activities
Principal payments on long-term debt	(426)	(413)
Proceeds from revolving credit facility	28,850	43,756
Principal payments on revolving credit facility	(32,977)	(43,106)
Net cash provided by (used by) financing activities	(4,553)	237
Decrease in cash and cash equivalents		(383)
Cash and cash equivalents, beginning of year		383
Cash and cash equivalents, end of period	$ 0	$ 0